NO154521C - Analogifremgangsmaate for fremstilling av nye, terapeutisk aktive piperidinderivater. - Google Patents

Analogifremgangsmaate for fremstilling av nye, terapeutisk aktive piperidinderivater.

Info

Publication number
NO154521C
NO154521C NO801014A NO801014A NO154521C NO 154521 C NO154521 C NO 154521C NO 801014 A NO801014 A NO 801014A NO 801014 A NO801014 A NO 801014A NO 154521 C NO154521 C NO 154521C
Authority
NO
Norway
Prior art keywords
preparation
therapeutically active
new therapeutically
analogy procedure
piperide
Prior art date
Application number
NO801014A
Other languages
English (en)
Norwegian (no)
Other versions
NO801014L (no
NO154521B (no
Inventor
Albert A Carr
Joseph E Dolfini
George J Wright
Original Assignee
Richardson Merrell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21845568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO154521(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Richardson Merrell Inc filed Critical Richardson Merrell Inc
Publication of NO801014L publication Critical patent/NO801014L/no
Publication of NO154521B publication Critical patent/NO154521B/no
Publication of NO154521C publication Critical patent/NO154521C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO801014A 1979-04-10 1980-04-09 Analogifremgangsmaate for fremstilling av nye, terapeutisk aktive piperidinderivater. NO154521C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/028,813 US4254129A (en) 1979-04-10 1979-04-10 Piperidine derivatives

Publications (3)

Publication Number Publication Date
NO801014L NO801014L (no) 1980-10-13
NO154521B NO154521B (no) 1986-06-30
NO154521C true NO154521C (no) 1986-10-08

Family

ID=21845568

Family Applications (2)

Application Number Title Priority Date Filing Date
NO801014A NO154521C (no) 1979-04-10 1980-04-09 Analogifremgangsmaate for fremstilling av nye, terapeutisk aktive piperidinderivater.
NO1998017C NO1998017I1 (no) 1979-04-10 1998-05-29 Fexofenadine

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1998017C NO1998017I1 (no) 1979-04-10 1998-05-29 Fexofenadine

Country Status (19)

Country Link
US (1) US4254129A (enExample)
JP (1) JPS55141469A (enExample)
AT (1) AT376208B (enExample)
AU (1) AU531146B2 (enExample)
BE (1) BE882703A (enExample)
CA (1) CA1123438A (enExample)
CH (1) CH643245A5 (enExample)
DE (1) DE3007498A1 (enExample)
DK (1) DK153709C (enExample)
ES (1) ES489934A0 (enExample)
FR (1) FR2453854A1 (enExample)
IL (1) IL59158A (enExample)
IT (1) IT1143960B (enExample)
NL (2) NL190580C (enExample)
NO (2) NO154521C (enExample)
NZ (1) NZ192653A (enExample)
PH (1) PH17023A (enExample)
SE (1) SE448726B (enExample)
ZA (1) ZA80332B (enExample)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
CN1053570C (zh) 1987-10-07 2000-06-21 默尔多药物公司 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US4908372A (en) * 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
AR245888A1 (es) * 1989-01-23 1994-03-30 Merrell Pharma Inc Procedimiento para la preparacion de una composicion farmaceutica liquida de derivados de piperidinoalcanol.
DE3917241A1 (de) * 1989-05-26 1990-11-29 Schaper & Bruemmer Gmbh 4-(hydroxydiphenylmethyl)-1-piperidyl-phenylalkan-derivate
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
TW198008B (enExample) * 1991-04-08 1993-01-11 Green Cross Corp
HU211019B (en) * 1991-12-02 1995-09-28 Richter Gedeon Vegyeszet Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds
EP0626968B1 (en) * 1992-02-13 2001-09-26 Merrell Pharmaceuticals Inc. Piperidinyl thiacyclic derivatives
US5631375A (en) * 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
DE69332117T2 (de) * 1992-04-10 2003-01-30 Merrell Pharmaceuticals Inc., Cincinnati 4-diphenylmethylpiperidine und verfahren zu ihrer herstellung
EP0639976B1 (en) * 1992-05-11 2000-07-26 Merrell Pharmaceuticals Inc. Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
RO116043B1 (ro) * 1992-08-03 2000-10-30 Sepracor Inc Compozitie farmaceutica
US5654433A (en) * 1993-01-26 1997-08-05 Merrell Pharmaceuticals Inc. Process for piperidine derivatives
US20020007068A1 (en) * 1999-07-16 2002-01-17 D'ambra Thomas E. Piperidine derivatives and process for their production
DK1369409T3 (da) * 1993-06-24 2006-08-14 Amr Technology Inc Fremgangsmåde til fremstilling af forbindelser, der er anvendelige som mellemprodukter
EP2261208A1 (en) 1993-06-25 2010-12-15 Aventisub II Inc. Intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives
US6147216A (en) * 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
KR100338877B1 (ko) * 1993-10-25 2002-12-05 메렐 파마슈티칼스 인크. 테르페나딘과이부프로펜의안정한약제학적조성물
ES2149357T3 (es) * 1994-05-16 2000-11-01 Merrell Pharma Inc Procedimiento y sales diastereomeras utiles para la resolucion optica del acido 4-(4-((hidroxidifenilmetil)-1-piperidinil)-1-hidroxibutil)-alfa,alfa-dimetilbenceno acetico racemico.
CN101497581B (zh) * 1994-05-18 2012-07-11 安万特萨博Ⅱ有限公司 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法
CA2189007C (en) * 1994-05-18 2004-03-02 Daniel R. Henton Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CN1067385C (zh) 1994-08-25 2001-06-20 默里尔药物公司 用于治疗变应性疾病的新的取代的哌啶类化合物
DK0812195T3 (da) * 1995-02-28 2003-03-03 Aventis Pharma Inc Farmaceutisk sammensætning til piperidinoalkanolforbindelser
AU705427B2 (en) * 1995-05-08 1999-05-20 Aventisub Ii Inc. Alpha-(substituted alkylphenyl) -4-(hydroxydiphenylmethyl)-1-piperidine butanol derivatives, their preparation and their use as anti-histamines, anti-allergy agents and bronchodilators
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
US5906747A (en) * 1995-11-13 1999-05-25 Biosepra Inc. Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6153754A (en) 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5925761A (en) * 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
EP0864653B1 (de) * 1997-03-11 2004-03-03 Aventis Pharmaceuticals Inc. Verfahren zur Herstellung von 4-(4-(4-(Hydroxydiphenyl)-1-piperidinyl)-1-hydroxybutyl)-alpha,alpha-dimenthylphenylessigsäure und phosphorylierter Derivate
JP4295913B2 (ja) * 1997-08-14 2009-07-15 アベンティス・ファーマスーティカルズ・インコーポレイテツド フェキソフェナジンおよびその誘導体のバイオアベイラビリティーを強化する方法
US6451815B1 (en) 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
CZ295461B6 (cs) * 1997-08-26 2005-08-17 Aventis Pharmaceuticals Inc. Farmaceutický prostředek ve formě dvouvrstvé tablety
DE59808753D1 (de) * 1997-12-17 2003-07-24 Aventis Pharma Gmbh Verfahren zur Alkylierung von Alkyl- oder Benzylcyanderivaten in Gegenwart von Trialkylaminen oder -phosphinen
HUP0101369A3 (en) * 1997-12-23 2002-11-28 Schering Corp Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
JP2002519411A (ja) * 1998-07-02 2002-07-02 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な抗ヒスタミン性ピペリジン誘導体およびその製造のための中間体
US6700012B2 (en) 1998-07-02 2004-03-02 Aventis Pharmaceuticals Inc. Antihistaminic piperidine derivatives and intermediates for the preparation thereof
US6683094B2 (en) 1998-07-02 2004-01-27 Aventis Pharmaceuticals Inc. Antihistaminic piperidine derivatives and intermediates for the preparation thereof
AU2007200674C1 (en) * 1998-07-02 2011-02-24 Aventisub Llc Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
IN191492B (enExample) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US6613906B1 (en) * 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US6613907B2 (en) 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms
CH695216A5 (de) * 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
KR20040012747A (ko) * 2001-04-09 2004-02-11 테바 파마슈티컬 인더스트리즈 리미티드 펙소페나딘 염산염의 다형체
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
CZ20033358A3 (en) 2001-06-18 2004-04-14 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl] -1-hydroxybutyl] -a,a-dimethylbenzene acetic acid and its hydrochloride
US20030158227A1 (en) * 2001-11-08 2003-08-21 Barnaba Krochmal Polymorphs of fexofenadine base
WO2003039482A2 (en) * 2001-11-08 2003-05-15 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine base
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
ES2239554T1 (es) * 2002-06-10 2005-10-01 Teva Pharmaceutical Industries Ltd. Forma xvi polimorfica de hidrocloruro de fexofenadina.
CN1741981A (zh) * 2002-12-16 2006-03-01 兰贝克赛实验室有限公司 非索那汀的制备方法
CA2514610A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Process for the preparation of fexofenadine
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
CA2560882A1 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
WO2006008567A1 (en) * 2004-06-18 2006-01-26 Wockhardt Limited Pharmaceutical compositions for piperidinoalkanol compounds
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
US7498443B2 (en) * 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
US7498345B2 (en) * 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
ES2704482T3 (es) 2004-11-24 2019-03-18 Meda Pharmaceuticals Inc Composiciones que comprenden azelastina y sus métodos de uso
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP2008120684A (ja) * 2005-03-07 2008-05-29 Kumamoto Univ 抗アレルギー薬
JP5133244B2 (ja) * 2005-08-05 2013-01-30 ルピン・リミテッド フェキソフェナジンの経口用医薬懸濁組成物
US20080292584A1 (en) * 2005-10-14 2008-11-27 Mutual Pharmaceutical Company, Inc. Metaxalone products, method of manufacture, and method of use
US20070088065A1 (en) * 2005-10-14 2007-04-19 Jie Du Metaxalone products, method of manufacture, and method of use
RU2283649C1 (ru) * 2005-10-27 2006-09-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
WO2007049303A2 (en) * 2005-10-28 2007-05-03 Ind-Swift Laboratories Limited An improved process for the preparation of highly pure fexofenadine
RU2008122978A (ru) 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
CN100443470C (zh) * 2006-07-21 2008-12-17 杭州保灵有限公司 一种依巴斯汀的制备方法
ITMI20061491A1 (it) * 2006-07-27 2008-01-28 Archimica Srl Processo per la preparazione di fexofenadina.
ITMI20061492A1 (it) * 2006-07-27 2008-01-28 Archimica Srl Processo per la preparazione di fexofenadina.
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
ES2534588T3 (es) 2007-04-13 2015-04-24 Southern Research Institute Terfenadina como agente antiangiogénico
ITMI20070987A1 (it) * 2007-05-16 2008-11-17 Dipharma Francis Srl Procedimento per la preparazione di composti chetonici
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
EP2105134A1 (en) 2008-03-24 2009-09-30 Ranbaxy Laboratories Limited Stable amorphous fexofenadine hydrochloride
KR20110017365A (ko) * 2008-05-30 2011-02-21 페어필드 클리니컬 트라이얼즈 엘엘씨 피부 염증 및 변색을 위한 방법 및 조성물
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
CN101585805B (zh) * 2009-06-06 2011-07-06 浙江大学宁波理工学院 一种抗过敏药物非索非那定盐酸盐的制备方法
EP2289867A3 (en) 2009-08-19 2012-04-25 Jubilant Organosys Limited A process for producing 4-(4-halo-1-oxybutyl)-alpha,alpha-dimethylbenzene acetic acid or alkyl esters thereof
CN101671292B (zh) * 2009-10-10 2011-09-07 浙江大学宁波理工学院 盐酸非索非那定的合成方法
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
EP2371817A1 (en) * 2010-04-01 2011-10-05 Arevipharma GmbH Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof
US9216955B2 (en) 2010-06-15 2015-12-22 Chemelectiva S.R.L. Polymorphic form of Fexofenadine hydrochloride, intermediates and process for its preparation
JP5925301B2 (ja) 2011-05-23 2016-05-25 サノフイ Ｎ−アルキル基を含有するジュウテリウム化化合物の製造方法
JP5362151B2 (ja) 2011-09-29 2013-12-11 塩野義製薬株式会社 Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CN102659667B (zh) * 2012-04-20 2013-08-14 浙江启明药业有限公司 一种非索非那定关键中间体的合成方法
CN103333100B (zh) * 2013-06-06 2016-04-06 池州东升药业有限公司 一种盐酸非索非那定的合成工艺
ITMI20131652A1 (it) 2013-10-07 2015-04-08 Dipharma Francis Srl Procedimento per la purificazione di derivati dell'acido 2-fenil-2-metil-propanoico
CN104557671B (zh) * 2013-10-10 2018-04-13 池州东升药业有限公司 一种非索非那定及中间体的合成方法
EP2949321A1 (en) 2014-05-26 2015-12-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer formulations of fexofenadine and montelukast
RS58961B1 (sr) 2015-01-22 2019-08-30 Sanofi Aventis Deutschland Proces proizvodnje 2-[4-(ciklopropankarbonil)fenil]-2-metil-propannitrila
DK3365327T3 (da) 2015-10-22 2020-02-24 Sanofi Aventis Deutschland Fremgangsmåde til fremstilling af fexofenadin og mellemprodukter, der anvendes deri
GB2629127A (en) 2022-08-31 2024-10-23 Novumgen Ltd An orodispersible tablet of fexofenadine and its process of preparation
US20250381137A1 (en) 2023-01-20 2025-12-18 Opella Healthcare Group Sas Paraben-free fexofenadine formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242169A (en) * 1969-04-09 1971-08-11 Ucb Sa Piperidine derivatives
US3806526A (en) * 1972-01-28 1974-04-23 Richardson Merrell Inc 1-aroylalkyl-4-diphenylmethyl piperidines
BE794598A (fr) * 1972-01-28 1973-05-16 Richardson Merrell Inc Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
ZA728544B (en) * 1972-01-28 1974-02-27 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US3965257A (en) * 1972-01-28 1976-06-22 Richardson-Merrell Inc. Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions
BE794596A (fr) * 1972-01-28 1973-05-16 Richardson Merrell Inc Piperidinoalcanone-oximes substituees et leur procede de preparation
US3941795A (en) * 1974-02-08 1976-03-02 Richardson-Merrell Inc. α-ARYL-4-SUBSTITUTED PIPERIDINOALKANOL DERIVATIVES
US3931197A (en) * 1974-02-08 1976-01-06 Richardson-Merrell Inc. Substituted piperidine derivatives
US3946022A (en) * 1974-03-04 1976-03-23 Richardson-Merrell Inc. Piperidine derivatives
US3922276A (en) * 1974-12-11 1975-11-25 Robins Co Inc A H 1-Substituted-4-benzylidenepiperidines
US3956296A (en) * 1974-12-11 1976-05-11 A. H. Robins Company, Incorporated 1-Substituted-4-benzylpiperidines

Also Published As

Publication number Publication date
IL59158A (en) 1984-04-30
NZ192653A (en) 1982-03-16
NO1998017I1 (no) 1998-05-29
DE3007498A1 (de) 1980-10-23
IL59158A0 (en) 1980-05-30
IT1143960B (it) 1986-10-29
SE8002634L (sv) 1980-10-11
IT8048245A0 (it) 1980-03-24
FR2453854B1 (enExample) 1983-06-24
AU531146B2 (en) 1983-08-11
JPH0132823B2 (enExample) 1989-07-10
CH643245A5 (de) 1984-05-30
FR2453854A1 (fr) 1980-11-07
CA1123438A (en) 1982-05-11
NO801014L (no) 1980-10-13
ES8103735A1 (es) 1981-03-16
BE882703A (fr) 1980-07-31
NO154521B (no) 1986-06-30
NL190580C (nl) 1994-05-02
US4254129A (en) 1981-03-03
PH17023A (en) 1984-05-11
NL190580B (nl) 1993-12-01
SE448726B (sv) 1987-03-16
DE3007498C2 (enExample) 1989-09-07
NL980013I1 (nl) 1998-06-02
ATA144880A (de) 1984-03-15
DK153709B (da) 1988-08-22
DK132980A (da) 1980-10-11
JPS55141469A (en) 1980-11-05
AU5501680A (en) 1980-10-16
ES489934A0 (es) 1981-03-16
DK153709C (da) 1988-12-27
ZA80332B (en) 1981-01-28
NL980013I2 (nl) 1998-10-01
NL8000754A (nl) 1980-10-14
AT376208B (de) 1984-10-25

Similar Documents

Publication Publication Date Title
NO154521C (no) Analogifremgangsmaate for fremstilling av nye, terapeutisk aktive piperidinderivater.
NO154964C (no) Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive piperidinderivater.
NO151085C (no) Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive peptidylargininaldehydderivater
NO153136C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive naftyridinderivater.
NO154883C (no) Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive 2-acylaminomethyl-1,4-benzodiazepiner.
NO152841C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive nye 4-aroylimidazol-2-oner.
NO152899C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive glycerolderivater.
NO152215C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4,5-diaryl-2-nitroimidazoler
NO149102C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-4-fenyl-1,2,3,4-tetrahydro-1-naftalenamin-derivater
NO871879D0 (no) Fremgangsmaate for fremstilling av nye, terapeutisk aktive heterocykliske forbindelser.
NO144455C (no) Fremgangsmaate ved fremstilling av terapeutisk aktive nye piperidinderivater.
NO145379C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n2-arylsulfonyl-l-argininamider.
NO156787C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater.
NO153496C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive indolizin-derivater.
NO150884C (no) Analogifremgangsmaate for fremstilling av nye, terapeutisk aktive imidazotiazolderivater
NO148926C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive, nye merkaptoimidazolderivater
NO823520L (no) Fremgangsmaate ved fremstilling av nye, terapeutisk aktive carbohydrater.
NO800857L (no) Fremgangsmaate for fremstilling av nye antisekretorisk aktive forbindelser.
NO154268C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 6alfa-flour-9a-klor-prednisolon-17,21-diestere.
NO145198C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktivt 1,2-benzisotia-zolinon-3
NO154920C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive, nye pyridothienotriaziner.
NO160370C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive penam-1,1-dioksyd-forbindelser.
NO154396C (no) Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive halovincamonderivater.
NO152898C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive substituerte acetofenoner.
NO144457C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive dihydro-1,4-pyridiner